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Abstract
Genome-wide association studies (GWAS) have not been able to completely elucidate
the genetic background of complex diseases. Part of it could lie in repetitive sequences
not studied in the GWAS, as those corresponding to Human Endogenous Retroviruses
(HERVs). In the present work, we aim to review the potential role of HERVs in the
etiology of autoimmune diseases, especially in multiple sclerosis (MS); their potential
pathogenic role and their putative consideration as a good target for new treatments.
For this purpose, we carried out an in-depth literature review on HERVs, and we
integrated our previous findings about HERV-W, HERV-K18, and HERV-Fc1 and MS
susceptibility. The study was carried out by a systematic search from electronic
databases using the keywords “HERV,” “Multiple sclerosis,” “HERV-W,” “MSRV,”
“HERV-K,” “HERV-Fc1,” and “GNbAC1.”
Keywords: Multiple sclerosis, HERV, MSRV, GNbAC1
1. Introduction
1.1. HERVs
The endogenous retroviruses (ERVs) could be defined as “genetic parasites” of vertebrates [1],
given that their origin is very different from the one displayed by the rest of the genome. Their
existence in the genome of mammals is only known since 1970 [2], although, they resulted
from ancestral infections by exogenous retroviruses millions of years ago. During an infection,
the exogenous retroviruses are able to integrate one copy of their genome (provirus) into the
genome of the host. Thus, they can stay permanently associated with the host and be trans‐
mitted horizontally by the creation of new virions (the typical spread of an infectious virus).
Only when they infect a germ line cell, the integrated DNA can become part of the gene pool
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and be transmitted in a Mendelian fashion like ERVs [1, 3-5], as shown in Figure 1. Those who
are present in the human genome are named human endogenous retroviruses (HERVs).
The endogenization process profoundly impacts on the survival and evolution of the virus
and the host. It results from the balance achieved between the immune surveillance and the
virus virulence [6]. In this way, the HERVs must surpass the host’s antiviral defense mecha‐
nisms and infect the germ cells without causing a cytotoxicity that would prevent persistence
in the progeny of the host [6]. Furthermore, from this moment on, all host cells are carriers of
an integrated provirus [6].
Figure 1. The endogenization process: once the retrovirus infects a germ line cell, vertical transmission in a Mendelian
fashion occurs.
The retroviral insertion is aleatory, in the sense that no specific sites for retroviral integration
exist in the host genome. Nonetheless, due to the epigenetic chromatin packaging, integrated
HERVs elements are more commonly found within the transcriptionally active genome [6].
Currently, HERVs comprise nearly 8% of the human genome [7], distributed in approximately
31 independently acquired multigene families [8]. Even though no standard nomenclature has
been defined for HERVs, they have been classified based on their homology with different
groups of exogenous retroviruses. They are grouped as class I, class II, or class III retroviruses
considering their homology with Gamma and Epsilon retroviruses, Betaretrovirus or Spuma‐
virus, respectively [9, 10]. The family name is usually given by “HERV” followed by a one-
letter amino acid code that corresponds to the tRNA specific of the site used to initiate reverse
transcription [10]; consequently, the HERV-W family would use a tryptophan.
As mentioned, HERVs have a similar structure to proviruses of infectious retroviruses, with
three principal genes, gag, pol, and env, flanked by two long terminal repeats (LTRs) [6]. The
gag gene codes for the viral assembly proteins, including the nucleocapsid, matrix, and capsid
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proteins. The pol gene codes for the viral replication proteins, yielding the reverse transcriptase,
protease, ribonuclease, and integrase proteins. Finally, the env gene codes for a viral glyco‐
protein, with both a surface and a transmembrane subunit. However, important changes are
observed in the HERVs expression compared to that of exogenous retroviruses. Most HERVs
encode incomplete proteins and accumulate mutations and recombinations. Furthermore,
most HERVs with functional LTRs remain in a latent state under homeostatic conditions,
owing to the epigenetic silencing of the provirus in heterochromatin [11]. Exceptionally,
specific HERVs have been selected during evolution, provided that their biological functions
could be beneficial for the host. In these cases, HERVs suffer a “domestication,” meaning that
a foreign gene can be used for cellular functions of the host [12]. In this group, we find proteins
like Syncytin-1 from the HERV-W family, and Syncytin-2 from the HERV-FRD family [13].
These highly fusogenic envelope proteins are necessary to allow the formation of the placental
syncytiotrophoblast layer; furthermore, they could be involved in the immune tolerance to the
fetus [13].
In addition to these “domestic HERVs,” several studies show reactivation of HERVs under
pathologic conditions, such as different types of cancer [14-20]; autoimmune diseases includ‐
ing multiple sclerosis (MS) [21-37], rheumatoid arthritis (RA) [38], psoriasis [39], or systemic
lupus erythematosus (SLE) [40]; and other diseases like schizophrenia [41, 42]. Nonetheless,
we do not know whether their reactivation or increased expression is a causal effect, or
conversely, is an underlying consequence of the disease.
1.2. Potential expression mechanisms of HERVs
Many factors can interfere or modulate the expression of HERVs, such as recombination events
between two or more replication-defective HERVs [43, 44], infectious agents like Human
herpesvirus 6 (HHV6) [34, 45] and Epstein–Barr virus (EBV) [46, 47], several transcription
factors [31, 48], and the epigenomic context of the HERVs [6, 49, 50].
• Recombination events
Two or more replication-defective HERVs can restore their own defects through recombination
events, resulting in a replication-competent retrovirus [5]. Even though this is an infrequent
event, a study in mice points to a significantly increased frequency in specific immune
deficiencies [44]. Furthermore, it has been demonstrated that recombination between three
HERV-K defective proviruses is possible, leading to an infectious retrovirus [5, 43].
• Infectious agents
A putative explanation about the preferential expression of HERVs found in human brain
samples could be the tropism of specific viruses and bacteria to the central nervous system
(CNS). Neurotropic agents like herpesvirus [29, 51], Toxoplasma gondii [52], or certain strands
of influenza virus [53] are able to cross the hematoencephalic barrier into the CNS. Usually,
they are intercepted by cerebral macrophages leading to an abortive infection, but their
transient presence in the CNS could activate the HERVs expression as a consequence of their
immediate-early (IE) genes expression [4]. The expression of the IE genes of herpes simplex
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virus type 1 (HSV-1) and its interaction with the transcription factor binding sites situated in
the U3 region of the LTR, such as AP-1 [54] and Oct-1 [55], lead to an activation of transcription
in HERV-K and HERV-W families.
The herpesviruses are one of the best candidates: they may be neurotropic, remain latent, and
can be reactivated. Furthermore, the expression of the Env epitopes in the surface of B cells
and monocytes could be a consequence of the interaction between HERVs and herpesviruses
[25]. Thus, the herpesviruses could play a dual role in neurodegenerative diseases, acting as
pathological entities per se and as inducers of HERVs [6].
• Transcription factors
An important component of the antiviral innate immunity is the regulation of the expression
and replication of HERVs by different transcription factors [48]. In HERV-W and HERV-K
elements, both families previously related to multiple sclerosis (MS), different binding sites
for transcription factors such as NF-Kβ [31, 48] are located in their promoter regions and could
drive an increased expression of HERVs during inflammation.
• Epigenomic context
The chromatin state as well as the methylation state of GpC islands within the HERV promoter
and regulatory regions seem to be crucial factors in the control of HERVs expression [49, 50].
Both play an important role as a part of the defense system against the potential effects of
inserted sequences. Previously published studies describe how proviruses and solitary LTRs
are densely methylated under physiological conditions, but hypomethylated in placenta [49,
50]. Thus, DNA hypomethylation, as observed in certain types of cancer, could allow reacti‐
vation of retroelements. In MS, HERVs have been described as susceptible elements to undergo
epigenetic modifications, mainly due to modifications in the methylation state, resulting in
activation of their expression and, consequently, inappropriate activation of the immune
system.
1.3. Pathogenic mechanisms of HERVs
Even though most inserted copies in the human genome are defective copies, some HERVs
could maintain the potential to cause or contribute to disease by different mechanisms [5]. As
mentioned, HERVs may alter cellular functions by two ways, either acting as a genetic element
or as a viral pathogen [6].
• Gene disruption
HERVs, like transposons, are able to experience transposition, recombination, and integration
cycles. Some HERVs families include a high number of copies in the genome. It is believed that
these families have been spread around the genome through the reintegration of a provirus.
However, each new integration process increases the risk of a harmful insertion. They can
disrupt genes present in their integration sites, for example, HERV-K integrations have been
identified into tumor suppressor genes like BRCA2 and into the repair XRCC1 gene [6, 56].
• Modulation of gene expression
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Some HERVs conserve regulatory sequences that can operate as functional promoters,
enhancers, or polyadenylation signals, so they could change the expression of adjacent or distal
genes [4]. They can also form part of regulatory RNAs: microRNAs (miRNA), small interfering
RNAs (siRNA), and long intergenic noncoding RNAs (lincRNAs), contributing to the complex
regulatory network of gene expression [5]. Furthermore, HERVs integrated into introns can
provide alternative transcription start and termination sites [5].
• Pattern recognition receptors (PRRs)
The HERVs expression products, both nucleic acids and proteins, can modulate immune
responses. They have the potential to interact with components involved in the immune innate
response and to activate proinflammatory signaling pathways [57, 58]. Therefore, certain
HERVs proteins could directly interact with specific toll-like receptors (TLRs), for example
with TLR4, resulting in the production of TNFα and proinflammatory cytokines [58-60]. The
nucleic acids derived from HERVs may also activate cytosolic PRRs; in this way, both an
increased expression of RNA and the presence of cDNA in a nonfamilial compartment like the
cytosol could activate PRRs [60]. Nonetheless, the human being has coevolved with endoge‐
nous retroelements and this could have shaped the sensibility of DNA sensors of the innate
immune system, leading to an increased cDNA detection threshold to avoid an immune
response against them. The cDNA levels are restrained by the action of gene products like
Trex1 or SAMHD1 [60] and a loss-of-function mutation in these enzymes could result in the
cDNA accumulation and the consequent sensors activation. This process would lead to a
chronic immune response with release of pathogenic type I IFN and inflammatory mediators,
similar to those observed in autoimmune diseases [60].
• Viral proteins: molecular mimicry, superantigen activity, or immunosuppressive proteins
HERVs proteins hold epitopes to B and T cells and molecular mimicry between viral proteins
and certain autoantigens may exist, resulting in an autoimmune response. Moreover, some
HERVs sequences are able to encode for superantigens. Superantigens combine with MHC
class-II molecules to form ligands that stimulate T cells [61], and this may end in an abnormal
activation of autoreactive T lymphocytes [62].
Alternatively, evidences exist of the immunosuppressive activity of certain HERVs Env
proteins [63, 64]. This activity is reminiscent of their exogenous antecessors, which in this way
increased the viability of the virions in the host. This capacity has suffered an adaptation
process, and nowadays it might be implicated in the materno-fetal tolerance and could also
prevent the immune response to exogen pathogens and tumors [60].
• Retroviral help for B cells
HERVs can also help B cells to quickly produce antibodies directed against pathogenic antigens
[65]. The bacterial polysaccharide antigens and the carbohydrates linked to viral glycoproteins
have the ability to stimulate B cells in the absence of T-cell help. These antigens are called
thymus-independent antigens (TI), and they can be classified into two types: TI-1 or TI-2
antigens. TI-2 antigens cause extensive cross-linking of the BCR, leading to a quick differen‐
tiation of B cells into plasma cells. Finally, these plasma cells secrete protective antibodies, IgM
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and IgG [66]. However, the mechanism by which the TI-2 antigens activate B cells in the
marginal zone without the help of T cells still remains poorly understood. It has been recently
described that the cross-linking of B cells activates a signaling cascade, including the Bruton
Tyrosine Kinase and the nuclear transcription factor NF-Kβ, allowing transcription of endog‐
enous retroviral DNA [66]. The retroviral RNA may activate B cells by two complementary
but different pathways: first, it could activate the retinoic-acid-inducible gene 1 receptor
(RIG-1), resulting in a mitochondrial antiviral-signaling (MAVS); second, the RNA can be
converted into DNA and can activate the cyclic GMP-AMP synthase (cGAS, cGAMP synthase).
Finally, both signaling pathways would finish in the antigen-specific B-cell activation [65, 66].
2. HERVs and autoimmune diseases
HERVs represent the immunological limit between the self and the foreign. Their peculiar
origin is very different from that of other genome elements, as they can share properties with
infectious agents. Indeed, in case they would produce particles, these would not be so different
from those originated from exogenous retroviruses. Therefore, they could activate the immune
system and would induce autoimmunity [67]. As it has been previously discussed, HERVs
have been associated, among other infectious or neurologic diseases, with different autoim‐
mune diseases like MS [21-37], RA [38], psoriasis [39], T1D [68], or SLE [40], as shown in Table
1. Genome-wide association studies (GWAS) showed the existence of a genetic basis shared
between different autoimmune diseases, discovering new immunogenic mechanisms impli‐
cated, and HERVs could be part of these shared genetic elements.
Class Family PBS Related diseases Expression mechanisms Pathogenic mechanisms
I HERV-W Trp
MS
Schizophrenia
HIV
Osteoarthitis
Herpesviruses
Transcription factors
Toxoplasma gondii
Influenza A virus
Pro-inflammatory Env protein
Superantigen activity
OPCs differentiation
interference
Altered glial function
I HERV-F Phe MS Demethylating agents Superantigen activity
I HERV-H His
3q13.31
microdeletion
syndrome
N/A Genetic deletion byrecombination
I HERV-E Glu SLE Hypomethylation Immunosupressor potential ofEnv
I HERV-P Pro Cancer Unkown Unknown
II HERV-K Lys
MS
ALS
HIV
Herpersviruses
HTLV-1
Type 1 IFN
Superantigen activity
Neoepitopes
Genes disruption
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Class Family PBS Related diseases Expression mechanisms Pathogenic mechanisms
Schizophrenia
T1D
RA
Juvenil arthitis
Cancer
Transcription factors
Hypomethylation
MS, multiple sclerosis; HIV, human immunodeficiency virus; SLE, Systemic lupus erythematosus; ALS, amyotrophic
lateral sclerosis; T1D, type 1 diabetes; RA, rheumatoid arthritis, HTLV-1, human T-lymphotropic virus-1; IFN, interferon;
Env, envelope; OPCs, olygodendrocyte precursor cells; N/A, not applicable. Based on Douville and Nath, 2014 [6].
Table 1. HERVs families associated with different diseases
3. HERVs and MS
MS is one of the conditions more frequently related with HERVs. It is a chronic progressive
disease characterized by neuroinflammation in the CNS accompanied by demyelination,
axonal damage, and progressive neurologic dysfunction [69]. It is a complex disease, origi‐
nated from the interaction of genetic, environmental, and epigenetic factors [70]. Recently, its
incidence seems to be increased; at present MS affects 2.3 million people in the world [71].
However, many aspects of its pathogenesis are still poorly understood. GWAS have not
completely explained the MS genetic background [72-74], albeit including the ImmunoChip
Project [75] a total of 110 single nucleotide polymorphisms (SNPs) have been associated with
MS susceptibility. Even considering the strongest risk factor, the HLA-DRB1*15:01 allele, each
SNP has a modest effect and all together are able to explain only 20–28% of MS heritability [75].
Part of the missing heritability could reside on HERVs, as repetitive regions were not analyzed
in the GWAS. Those repetitive regions were previously considered as “junk DNA” because it
was thought that they had little or no physiological role. However, nowadays we know that
these sequences could play an important role in the development of autoimmune diseases,
including MS.
In 1989, Perron et al. [76] described the presence of extracellular virions associated with reverse
transcriptase activity in a culture of leptomeningeal cells (LM7) obtained from the cerebrospi‐
nal fluid (CSF) of an MS patient. In the beginning, it was thought that those virions could
correspond to the human T-lymphotropic virus (HTLV-1) due to the similarities between the
tropical spastic paraparesis (a demyelinating progressive disease) caused by HTLV-1, and MS.
However, a new retroviral element called MSRV (Multiple-sclerosis-associated retrovirus) was
identified, the founder of the HERV-W family [77]. This multicopy family, consisting of
approximately 650 loci around the human genome [35], comprises a total of 311 inserts (more
or less complete proviruses or pseudogenes) and 343 additional HERV-W LTRs [78].
Only the env gene mapping on chromosome 7, encoding Syncytin, presents a complete open
reading frame (ORF) and has been selectively conserved [35]. The MSRV env sequence can be
differentiated from the one corresponding to Syncytin-1 by a 12-nucleotide insertion in the
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transmembrane moiety. Both genes are expressed in the brain of MS patients, but the MSRV-
type env DNA copies were found sixfold more frequently in MS patients than in healthy
controls, while comparable copy numbers of Syncytin-1 were observed [79]. Furthermore,
Syncytin-1 is originated from the retroviral copy inserted in chromosome 7, and the pathogenic
protein MSRV-type Env could be originated from several integrations in the human genome,
or it could result from recombination events between insertions in different chromosomes [80,
81]. The genomic origin of HERV-W Env remains unknown although recent works consider
the copy mapping to chromosome X one plausible candidate [4, 80, 81]. This copy, located on
Xq22.3, would encode for an almost complete MSRV-type protein, truncated on its N-terminal
end due to the presence of a stop codon mutation at position 39 [81]. Ex vivo, this copy still
conserves coding capacity, as it is able to produce a truncated N-terminally Env protein [80].
Furthermore, the reversion of this stop codon would lead to a complete protein with signal
peptide, expressed in the cellular surface in the same way that Syncytin [80].
Recently, a genetic screening was performed by specific PCR amplification followed by High
Resolution Melting (HRM) analyses of the two MSRV-like env copies which show the ORF
with the highest length similarity and homology to Syncytin (1614 bp), inserted in chromosome
X (1428 bp) and in chromosome 20 (1419 bp). Both chromosomal origins show similar lengths
of their respective ORFs, 10% shorter than the one measured for Syncytin, and could putatively
originate functional proteins. The results pointed to the insertion in chromosome X, and not
the one in chromosome 20, as an origin of MSRV. One polymorphism identified in chromosome
X, rs6622139*T, was associated in women with MS susceptibility and severity [82], and it was
also associated with higher MSRV-like env levels of expression (Mann–Whitney U test:
p=0.003), while the two polymorphisms found in chromosome 20 did not show evidence of
association [83].
Since it was described, several studies have associated the HERV-W family with MS: the
presence of MSRV-type Env protein has been found in demyelinated acute lesions in MS
patients [31], as well as an increased number of DNA copies [84] or a higher prevalence of
MSRV-type RNA in serum and CSF of MS patients compared with patients suffering from
other neurological diseases or healthy controls from all ethnic groups [24, 27, 28, 31, 84-86].
The MSRV presence in serum and CSF is correlated with the clinical progression, severity, and
prognosis of MS [28, 46], while the absence of MSRV relates with a more stable course of the
disease [28, 36]. The MSRV production is stimulated by cytokines like TNFα, IL6, and
IFNγ[87], and current MS therapies like IFN-β and Natalizumab, which are able to reduce MS
symptomatology, promote a diminution of MSRV virus load levels in blood [87-89].
HERV-W Env proteins, MSRV-type Env, and Syncytin have proinflammatory and superanti‐
genic properties. They can cause neuroinflammation, neurodegeneration, immune system
dysregulation, and endoplasmic reticulum stress [4, 21, 22, 58, 90, 91]. Their pathogenicity has
been studied in vitro using different types of cell cultures and in vivo using a humanized Severe
Combined Immunodeficiency Disease (SCID) animal model, showing neurotoxic effects in
both settings [22, 92] and a reduced capacity of olygodendrocyte progenitor cells (OPC)
differentiation, interfering in the remyelination process [57]. A recent study clarifies the
possible pathogenic mechanisms of MSRV. In a human model of BBB, the endothelial cell line
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HCMEC/D3, they show that MRSV-type Env interacts with TLR4 and induces a dose-
dependent overexpression of ICAM1, as well as an induced IL6 and IL8 production; while the
Env protein derived from Syncytin-1 did not show these effects [59]. Furthermore, they also
described that the MSRV-type Env presence significantly stimulates the adhesion and
migration of activated immune cells through the layer of endothelial cells. These results
support the hypothesis that MSRV can be involved in MS pathogenesis, as well as in other
chronic inflammatory diseases, at least in the maintenance of the underlying inflammatory
condition [59]. Table 2 reflects the possible pathogenic mechanisms described for MSRV.
Cell type Receptor Pathogenic mechanisms
T lymphocytes TCR Superantigen activity, T lymphocytes proliferationand CK liberation
APC TLR4 ↑  pro-inflammatory CK↑  costimulatory molecules
HCMEC/D3 endothelial cell line TLR4 ↑  ICAM1 expressionIL6, IL8 expression
OPC TLR4 OPCs differentiation interference ( ↑  iNOS, oxidativestress)
APC, antigen presenting cell; OPC, olygodendrocyte precursor cell; TCR, T-cell receptor; TLR4, toll-like receptor 4
Table 2. Known pathogenic mechanisms of MSRV
Even though the HERV-W family is one of the HERV families more related to MS, other
families like HERV-K18 [37, 93] or HERV-Fc1 [29, 94, 95] have also been associated with MS
susceptibility.
HERV-K is a multicopy family including approximately 332 copies dispersed through the
human genome. It is the only known retroviral element that codes for all the structural and
enzymatic proteins (Gag, Prt, Pol), as well as for the Env protein and for the accessory Rec
protein [96]. This family has been related with different autoimmune diseases as MS [37],
type-1diabetes (T1D) [68], or juvenile rheumatoid arthritis [38]; and different cancer types
[14-17]. One specific member of this family, HERV-K18, has been associated with MS suscept‐
ibility and its expression is induced by herpesvirus [97, 98] and by EBV [99-102], both viruses
previously proposed as potential environmental factors involved in MS development [45, 51,
97, 103-108]. Three different variants of the HERV-K18 copy mapping to chromosome 1 [37]
have been described. They conform haplotypes within the first intron of CD48 that can be
defined by two SNPs (18.1 SNP1*A/SNP2*A, 18.2 SNP1*G/SNP2*G, 18.3 SNP1*A/SNP2*G), all
of them coding for an Env protein with superantigenic properties. However, only one of these
variants (18.3) has been associated with a higher risk to MS [37] and with an overall higher
susceptibility to autoimmune diseases, as described by a meta-analysis including a total of
2656 patients and 2016 controls [93].
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Considering the HERV-Fc family, a total of 6 HERV-Fc elements and 11 LTRs have been
identified across the human genome. Among them, only two elements correspond to a
complete HERV-Fc provirus (Fc1env and Fc2master) [109]. Related to MS, it has been observed
that the HERV-Fc1 RNA levels were significantly increased in the plasma of patients suffering
from active MS, compared to nonactive MS or controls [30]. The HERV-Fc1 is an unusual
provirus, because it includes a single copy in the genome, located on Xq21.33. Furthermore, it
is a recent acquisition for the genome, only present in humans, chimpanzees, and gorillas [109].
Nexo et al. [94] were the first to describe that rs391745, located in the promoter region of HERV-
Fc1, was associated with MS susceptibility in Danish cohorts and, then, a replication study was
performed with a Norwegian cohort. The latter study also detailed that the association was
only observed in the nonprimary-progressive MS forms [29], results validated in further
studies [95]. Regarding the HERV-Fc1 expression mechanisms, it has been observed that the
transcriptional expression levels of HERV-Fc1 RNA sequences are negatively correlated with
the methylation levels of CpG islands on the 5’ LTR region and, therefore, a higher HERV-Fc1
expression involves DNA demethylation [11, 110].
4. HERVs as future treatment options
An increased expression of HERVs in several autoimmune diseases [21-40, 68] and different
types of cancer [14-20], along with the decreased expression levels observed in successfully
treated patients with immunomodulatory therapies [88, 89] or chemotherapy [111] point to
the potential pathogenic role of HERVs and their putative consideration as a good target for
new treatments.
A humanized monoclonal antibody anti-Env-SU MSRV/HERV-W, GNbAC1, has been studied
as a putative MS treatment due to its potential neuroprotector effects [112-115]. The results of
a phase IIa clinical trial [114] show that the GNbAC1 treatment blocks the transcription of
proinflammatory genes mediated by Env, prevents the formation of nitrosantine, and restores
OPC differentiation. Furthermore, GNbAC1 has advantages compared to other MS treatments,
because the patients retain all their immune capacity. This treatment has also been studied in
other diseases like diabetes and schizophrenia.
The proteins encoded by HERV-K env have been proposed as therapeutic targets for different
types of cancer, due to the fact that a general hypomethylation of HERVs sequences has been
observed, as well as an increased expression of Np9 and Rec proteins originating from HERV-
K in different cancer cells [116]. Both proteins bind to the PLZF protein, a transcriptional
repressor of the C-MYC proto-oncogen. The inflammation and the deregulation of proto-
oncogen signaling caused by the HERV-K protein results in a protumorogenic microenviron‐
ment, which favors cell proliferation and metastasis [116]. The use of monoclonal antibodies
against HERV-K Env protein inhibits tumoral growth and induces apoptosis in breast cancer
cells in vitro [116]; therefore, it could be considered a good candidate as a therapy used together
with other cancer treatments.
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In addition to autoimmune diseases and cancer, the human immunodeficiency virus (HIV)
has been also related to HERVs, particularly with the HERV-K family, raising the issue of
potential beneficial effects of a therapy directed against HERVs in AIDS. Some studies report
an increased expression of HERV-K provirus in HIV patients compared to controls [117, 118]
and show that the immune responses against HERV-K decrease the HIV-1 viral load. In vitro,
the use of an antibody directed against the HERV-K transmembrane protein (HML-2), HA-137,
was able to eliminate the cells that displayed the antigen in their surface. This was carried out
by an antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism by natural killer
(NK) cells. It has been described that the HIV-infected cells display this membrane antigen in
their surface [119]; therefore, they would be potential targets of the antibody. The possibility
of finding a target epitope different from those of the HIV virus could open up opportunities
to the development of vaccines against this disease; a field that has been very limited due to
the high rate of mutation of the HIV [119].
5. Conclusion
This work aimed to provide a systematic revision of HERVs, with particular emphasis on their
potential pathogenic role in MS. Although many aspects of the etiology of this disease remain
to be solved, different works support the relevance that HERVs may have in the etiopatho‐
genesis of autoimmune diseases, and specifically in MS. HERVs may contribute to both,
disease onset and maintenance, through an exacerbated activation of the immune system.
Recently, the results of a phase IIa clinical trial that studies the effectiveness of a human
monoclonal antibody (GNbAC1) as a therapeutic target in MS have been published with
promising outcome. Thus, evidences support the role of HERVs as potential therapeutic
armory in different autoimmune diseases, cancer, and HIV.
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